Knut Brockow Selected Research

Mastocytosis

1/2022	Mast Cell Activation Syndromes: Collegium Internationale Allergologicum Update 2022.
1/2022	Global Classification of Mast Cell Activation Disorders: An ICD-10-CM-Adjusted Proposal of the ECNM-AIM Consortium.
1/2022	Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis.
3/2021	Molecular Background, Clinical Features and Management of Pediatric Mastocytosis: Status 2021.
2/2021	A Challenge for Allergologist: Application of Allergy Diagnostic Methods in Mast Cell Disorders.
1/2021	COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM).
10/2020	Low Frequency of IgE-Mediated Food Hypersensitivity in Mastocytosis.
12/2019	International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study.
1/2019	Adverse reactions to drugs and biologics in patients with clonal mast cell disorders: A Work Group Report of the Mast Cells Disorder Committee, American Academy of Allergy, Asthma & Immunology.
1/2019	Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Knut Brockow Research Topics

Disease

61	Hypersensitivity (Allergy) 11/2022 - 01/2002
46	Anaphylaxis (Anaphylactic Shock) 11/2022 - 01/2004
19	Mastocytosis 01/2022 - 01/2002
15	Drug Hypersensitivity (Drug Allergy) 11/2022 - 01/2002
7	Exercise-Induced Allergies 01/2022 - 04/2015
7	Systemic Mastocytosis 01/2022 - 08/2003
7	Atopic Dermatitis (Atopic Eczema) 01/2021 - 01/2002
6	Neoplasms (Cancer) 01/2022 - 08/2003
5	COVID-19 11/2022 - 11/2020
5	Asthma (Bronchial Asthma) 10/2021 - 01/2010
4	Immediate Hypersensitivity 11/2022 - 01/2006
4	Food Hypersensitivity (Food Allergy) 10/2022 - 01/2020
4	Mast Cell Activation Syndrome 01/2022 - 01/2013
4	Chronic Urticaria 01/2022 - 01/2011
4	Mast Cell Activation Disorders (Mast-Cell Disease) 01/2022 - 08/2012
4	Hereditary alpha-tryptasemia syndrome 01/2022 - 11/2020
3	Osteoporosis 01/2021 - 01/2002
3	Inflammation (Inflammations) 11/2020 - 05/2006
2	Urticaria (Hives) 01/2022 - 01/2021
2	Allergic Rhinitis 10/2021 - 01/2020
2	Syphilis 04/2021 - 01/2021
2	Exanthema (Rash) 11/2020 - 01/2020
2	Bites and Stings (Sting) 01/2020 - 01/2019
2	Drug-Related Side Effects and Adverse Reactions 01/2020 - 01/2008
2	Eosinophilic Esophagitis 01/2020 - 08/2014
1	Reinfection 11/2022
1	Cystic Fibrosis (Mucoviscidosis) 11/2022
1	Eosinophilia 02/2022
1	Hematologic Neoplasms (Hematological Malignancy) 01/2022
1	Disease Susceptibility (Diathesis) 01/2022
1	Herpes Zoster 01/2021
1	red meat allergy 01/2021
1	Mumps 01/2021
1	Rubella (German Measles) 01/2021
1	Pruritus (Itching) 01/2021
1	Measles 01/2021
1	Chickenpox 01/2021

Drug/Important Bio-Agent (IBA)

32	Immunoglobulin E (IgE)IBA 10/2022 - 01/2002
20	Tryptases (Tryptase)IBA 01/2022 - 01/2002
18	Pharmaceutical PreparationsIBA 01/2022 - 01/2002
16	Contrast MediaIBA 07/2022 - 04/2005
12	VaccinesIBA 11/2022 - 11/2012
12	AllergensIBA 01/2022 - 01/2004
9	Arthropod VenomsIBA 01/2022 - 01/2004
8	Biological ProductsIBA 01/2022 - 01/2002
6	COVID-19 VaccinesIBA 11/2022 - 01/2021
6	Anti-Bacterial Agents (Antibiotics)IBA 11/2022 - 10/2014
5	LactamsIBA 01/2022 - 10/2014
4	beta-LactamsIBA 11/2022 - 01/2020
4	Penicillins (Penicillin)FDA Link 01/2022 - 01/2020
4	Glutens (Glutelin)IBA 01/2022 - 04/2015
4	GliadinIBA 08/2021 - 04/2015
3	mRNA VaccinesIBA 11/2022 - 01/2022
3	Messenger RNA (mRNA)IBA 11/2022 - 01/2021
3	Coloring Agents (Dyes)IBA 01/2022 - 08/2014
3	EpitopesIBA 01/2022 - 09/2020
3	Omalizumab (Xolair)FDA Link 01/2022 - 01/2020
3	Epinephrine (Adrenaline)FDA LinkGeneric 03/2021 - 01/2010
3	Biomarkers (Surrogate Marker)IBA 01/2021 - 05/2005
3	AntibodiesIBA 09/2020 - 01/2004
3	VenomsIBA 01/2020 - 01/2014
2	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2022
2	4'-N,N-dimethylamino-4-aminoazobenzeneIBA 01/2021 - 01/2014
2	dupilumabIBA 01/2021 - 01/2021
2	Cephalosporins (Cephalosporin Antibiotics)IBA 11/2020 - 01/2020
2	SteroidsIBA 01/2020 - 08/2014
2	Immunoglobulin G (IgG)IBA 01/2020 - 01/2004
2	Immunoglobulins (Immunoglobulin)IBA 01/2020 - 08/2011
2	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2019 - 01/2019
2	Indicators and Reagents (Reagents)IBA 01/2019 - 01/2010
2	GadoliniumIBA 08/2014 - 08/2011
2	Eosinophil Cationic ProteinIBA 08/2014 - 01/2003
2	Histamine (Histamine Dihydrochloride)FDA Link 01/2014 - 01/2010
2	Peptide Hydrolases (Proteases)FDA Link 01/2008 - 05/2006
2	CytokinesIBA 01/2008 - 05/2006
2	Interleukin-6 (Interleukin 6)IBA 05/2005 - 01/2002
1	Monoclonal AntibodiesIBA 02/2022
1	S63845IBA 02/2022
1	venetoclaxIBA 02/2022
1	Tyrosine Kinase InhibitorsIBA 02/2022
1	Genetic Markers (Genetic Marker)IBA 01/2022
1	Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric 01/2022
1	Local Anti-Infective Agents (Antiseptics)IBA 01/2022
1	CosmeticsIBA 01/2022
1	gluteninIBA 08/2021
1	Histamine Receptors (Histamine Receptor)IBA 03/2021
1	Measles-Mumps-Rubella Vaccine (MMR Vaccine)IBA 01/2021
1	GelatinIBA 01/2021
1	Carboxymethylcellulose Sodium (Polycell)FDA Link 01/2021
1	CarbohydratesIBA 01/2021
1	Blocking AntibodiesIBA 11/2020
1	Infliximab (Remicade)FDA Link 09/2020

Therapy/Procedure

21	Therapeutics 01/2022 - 10/2004
4	Premedication 01/2022 - 04/2005
4	Injections 01/2022 - 09/2019
2	Critical Care (Surgical Intensive Care) 01/2021 - 01/2014
2	Drug Therapy (Chemotherapy) 01/2020 - 01/2020
2	Immunotherapy 01/2010 - 01/2004
1	Precision Medicine 11/2020
1	Off-Label Use 11/2020